Investigational drug · Phase 3
Divarasib
Also called: GDC-6036, RO7435846, RO743584
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer, Non-small Cell Lung Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
8
8 still active
All registered trials
14
Any phase or sponsor naming "Divarasib"
First trial start
2017
Sep 22, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Divarasib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Cancer
- KRAS G12C Lung Cancer
- Non-small Cell Lung Cancer
- Solid Tumors
- Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Divarasib" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03178552 · 1,000 participants (planned) · Start Sep 22, 2017 · Primary completion Jun 30, 2027
Drug: Alectinib; Atezolizumab and 10 more · For: Non-Small Cell Lung Cancer
Sites: Sacramento, California; Denver, Colorado; Fort Myers, Florida · 161 sites in all
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04589845 · 920 participants (planned) · Start Jan 18, 2021 · Primary completion Sep 25, 2032
Drug: Entrectinib; Entrectinib and 9 more · For: Solid Tumors
Sites: Goodyear, Arizona; Los Angeles, California; Newport Beach, California · 112 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06793215 · 600 participants (planned) · Start Oct 24, 2025 · Primary completion Nov 30, 2028
Drug: Divarasib; Pembrolizumab and 3 more · For: Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer
Sites: Anchorage, Alaska; Goodyear, Arizona; Clovis, California · 299 sites in all
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)Pivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04929223 · 542 participants (planned) · Start Oct 22, 2021 · Primary completion Aug 31, 2030
Drug: Inavolisib; Bevacizumab and 7 more · For: Metastatic Colorectal Cancer
Sites: Birmingham, Alabama; Phoenix, Arizona; Duarte, California · 84 sites in all
- A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)Pivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07541170 · 400 participants (planned) · Start Oct 6, 2026 · Primary completion Jan 31, 2032
Drug: Divarasib; Pembrolizumab and 1 more · For: Non-small Cell Lung Cancer
Sites: Clovis, California; Bay Pines, Florida; Atlanta, Georgia · 104 sites in all
- A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung CancerPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06497556 · 338 participants · Start Sep 23, 2024 · Primary completion May 19, 2026
Drug: Divarasib; Sotorasib and 1 more · For: Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer
Sites: Gilbert, Arizona; Los Angeles, California; San Francisco, California · 151 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05789082 · 320 participants (planned) · Start Jun 20, 2023 · Primary completion Jan 29, 2032
Drug: Divarasib; Pembrolizumab and 3 more · For: Non-Small Cell Lung Cancer
Sites: Duarte, California; Huntington Beach, California; Irvine, California · 71 sites in all
- A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05862285 · 200 participants (planned) · Start Jun 1, 2023 · Primary completion Mar 1, 2033
Drug: Ipatasertib; Tiragolumab and 7 more · For: Cancer
Sites: Charleroi, Belgium; Kortrijk, Belgium; Leuven, Belgium · 85 sites in all
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Active, not recruiting
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT04302025 · 99 participants (planned) · Start Nov 6, 2020 · Primary completion Nov 30, 2026
Drug: Alectinib; Entrectinib and 7 more · For: Non-small Cell Lung Cancer
Sites: Los Angeles, California; Orange, California; Sacramento, California · 24 sites in all
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT06734208 · 31 participants · Start Jan 31, 2025 · Primary completion Nov 27, 2025
Drug: Divarasib · For: Hepatic Impairment
Sites: Miami, Florida; Miami Lakes, Florida; Orlando, Florida · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Targeting RAS Signaling Pathways: Molecular Regulation, FDA-Approved Inhibitors, Clinical Advances, and Patent Innovations.
Chauhan A, Prajapati V, Singh AK, et al. · Drug Dev Res 2026
- Rapid target engagement of KRAS G12C tricomplex inhibitor RO3903 overcomes resistance and drives durable tumor regression.
Yao X, Wang S, Xie J, et al. · Proc Natl Acad Sci U S A 2026
- Divarasib outperforms first-generation KRAS-G12C inhibitors in NSCLC.
Romero D · Nat Rev Clin Oncol 2026
- Variant-Selective and Pan-RAS Inhibitors Enhance Targeted Agent Activity in Patient-Derived Multi-cell-type Tumor Spheroids.
Dexheimer TS, Davoudi Z, Coussens NP, et al. · Mol Cancer Ther 2026
- Divarasib Bests 1st-Generation KRASG12C Inhibitors.
· Cancer Discov 2026
- Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC.
Skoulidis F, Ahn MJ, Gadgeel S, et al. · N Engl J Med 2026
Also in development for Non-Small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.